Impact of medical therapy for hormone-secreting Pituitary tumors on bone
Authors' conclusion
More research is needed on the effectsof medical therapies for hormone secreting pituitary tumors on bone health.
Study context
- Population
- Patients with hormone-secreting pituitary tumors (acromegaly, prolactinoma, Cushing's disease)
- Comparison
- Medical therapies for hormone-secreting pituitary tumors and their effects on bone
- Outcome
- Effects of medical therapy on bone
Pooled result
As reported in the abstract
- Acromegaly: medical therapy lowers bone turnover marker (BTM) levels; Areal bone mineral density (aBMD) does not change or increases
- Acromegaly: Somatostatin-receptor ligand (SRL)- and pegvisomant-treated patients have persistently reduced volumetric BMD and peripheral microarchitectural abnormalities, similar to surgically-treated patients
- Acromegaly: fracture risk remains elevated with medical therapy but is lessened with biochemical control
- Prolactinoma: dopamine agonists associated with improved aBMD, not always fully normalized
- Prolactinoma (one cross-sectional study): lower total volumetric BMD and impaired microarchitecture despite dopamine agonist therapy
- Prolactin-secreting tumors: high VF rate lowered on cabergoline, but fracture rate of men and postmenopausal women higher than controls in some studies
- Cushing's disease: studies of modern-day medical therapy on bone are lacking
Original publication
Impact of medical therapy for hormone-secreting Pituitary tumors on bone. Pituitary. Published 5 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →